NRx Pharmaceuticals (NRXP) investor relations material

Executive summary

• Achieved significant regulatory and commercial progress, advancing preservative-free ketamine (KETAFREE) and NRX-101 toward FDA approval, and initiating commercial manufacturing at scale.

• Expanded clinical operations with five HOPE clinics, generating first patient service revenue post-Dura acquisition, and planning to reach eight or more clinics by end of Q2.

• Acquired or initiated acquisition of GeNeuro assets, adding a new platform for neurological and autoimmune diseases.

• Eliminated $8.7 million in debt and raised $7 million post-quarter, ensuring sufficient cash for immediate needs.

• Formed new subsidiaries, including NRx Defense Systems and GeNeuro, and appointed key leadership roles.

Financial highlights

• Net loss for Q1 2026 was $1.4 million ($0.04/share), a 74% reduction year-over-year from $5.5 million ($0.34/share) in Q1 2025.

• Net patient service revenue reached $1.1 million in Q1 2026, driven by the Dura acquisition.

• Loss from operations increased to $4.7 million from $3.8 million year-over-year, due to strategic investments.

• Research and development expense rose to $1.3 million from $0.8 million; general and administrative expense increased to $3.8 million from $2.9 million.

• Cash and equivalents stood at $6.7 million as of March 31, 2026, with $7 million raised subsequently.

Outlook and guidance

• Management expects current cash, anticipated clinic revenue growth, cost reduction initiatives, and at-the-market offering to support operations through at least 2026.

• KETAFREE approval targeted for summer/Q3 2026, with commercial launch preparations underway.

• NRX-100 NDA submission expected in Q2 2026, with FDA response on statistical analysis plan anticipated by month-end.

• MIND1 trial for NRX-101 plus TMS has FDA clearance and is expected to be supported by non-dilutive federal funding.

• Management anticipates continued operating losses through 2026 and may require additional financing.